Stayble Therapeutics AB (publ) (STABL.ST)

SEK 0.39

(1.56%)

Revenue Summary of Stayble Therapeutics AB (publ)

  • Stayble Therapeutics AB (publ)'s latest annual revenue in 2023 was - SEK , down 0.0% from previous year.
  • Stayble Therapeutics AB (publ)'s latest quarterly revenue in 2024 Q2 was - SEK , down -100.0% from previous quarter.
  • Stayble Therapeutics AB (publ) reported a annual revenue of - SEK in annual revenue 2022, down 0.0% from previous year.
  • Stayble Therapeutics AB (publ) reported a annual revenue of - SEK in annual revenue 2021, down 0.0% from previous year.
  • Stayble Therapeutics AB (publ) reported a quarterly revenue of - SEK for 2024 Q2, down -100.0% from previous quarter.
  • Stayble Therapeutics AB (publ) reported a quarterly revenue of - SEK for 2023 FY, down 0.0% from previous quarter.

Annual Revenue Chart of Stayble Therapeutics AB (publ) (2023 - 2016)

Historical Annual Revenue of Stayble Therapeutics AB (publ) (2023 - 2016)

Year Revenue Revenue Growth
2023 - SEK 0.0%
2022 - SEK 0.0%
2021 - SEK 0.0%
2020 - SEK -100.0%
2019 537.89 SEK -98.66%
2018 40.11 Thousand SEK 0.0%
2017 - SEK -100.0%
2016 35.5 Thousand SEK 0.0%

Peer Revenue Comparison of Stayble Therapeutics AB (publ)

Name Revenue Revenue Difference
Alligator Bioscience AB (publ) 58.1 Million SEK 100.0%
Ziccum AB (publ) 3.74 Million SEK 100.0%
Modus Therapeutics Holding AB (publ) - SEK NaN%
BioArctic AB (publ) 615.99 Million SEK 100.0%
Sprint Bioscience AB (publ) 50.48 Million SEK 100.0%
Mendus AB (publ) 28.48 Million SEK 100.0%
Genovis AB (publ.) 158.23 Million SEK 100.0%
Intervacc AB (publ) 8.01 Million SEK 100.0%
QuiaPEG Pharmaceuticals Holding AB (publ) 4.37 Million SEK 100.0%
Active Biotech AB (publ) - SEK NaN%
Magle Chemoswed Holding AB (publ) 170.44 Million SEK 100.0%
Bio-Works Technologies AB (publ) 43.89 Million SEK 100.0%
Aptahem AB (publ) 2.63 Million SEK 100.0%
Vicore Pharma Holding AB (publ) - SEK NaN%
Kancera AB (publ) 1.03 Million SEK 100.0%
Infant Bacterial Therapeutics AB (publ) 77 Thousand SEK 100.0%
Fluicell AB (publ) 3.33 Million SEK 100.0%
Saniona AB (publ) 16.84 Million SEK 100.0%
Lipigon Pharmaceuticals AB (publ) 16.4 Million SEK 100.0%
Biovica International AB (publ) 7.29 Million SEK 100.0%
Spago Nanomedical AB (publ) 1.2 Million SEK 100.0%
AcouSort AB (publ) 10.55 Million SEK 100.0%
Xintela AB (publ) 78 Thousand SEK 100.0%
Abliva AB (publ) 137 Thousand SEK 100.0%
Egetis Therapeutics AB (publ) 57.6 Million SEK 100.0%
Karolinska Development AB (publ) 2.01 Million SEK 100.0%
OncoZenge AB (publ) 3000.00 SEK 100.0%
Amniotics AB (publ) - SEK NaN%
2cureX AB (publ) 155 Thousand SEK 100.0%
CombiGene AB (publ) 5.54 Million SEK 100.0%
Asarina Pharma AB (publ) - SEK NaN%
Calliditas Therapeutics AB (publ) 1.2 Billion SEK 100.0%
Camurus AB (publ) 1.71 Billion SEK 100.0%
Corline Biomedical AB 25.03 Million SEK 100.0%
IRLAB Therapeutics AB (publ) 5.67 Million SEK 100.0%
Isofol Medical AB (publ) 721 Thousand SEK 100.0%
I-Tech AB 120.86 Million SEK 100.0%
Hansa Biopharma AB (publ) 134.09 Million SEK 100.0%
Cyxone AB (publ) 5.14 Million SEK 100.0%
ExpreS2ion Biotech Holding AB (publ) 7.05 Million SEK 100.0%
Biosergen AB - SEK NaN%
Cantargia AB (publ) - SEK NaN%
NextCell Pharma AB 10.66 Million SEK 100.0%
Xspray Pharma AB (publ) - SEK NaN%
Elicera Therapeutics AB (publ) 11.23 Million SEK 100.0%
Nanologica AB (publ) 1.44 Million SEK 100.0%
SynAct Pharma AB - SEK NaN%
Annexin Pharmaceuticals AB (publ) - SEK NaN%
LIDDS AB (publ) - SEK NaN%
Lipum AB (publ) 53 Thousand SEK 100.0%
BioInvent International AB (publ) 71.46 Million SEK 100.0%
Alzinova AB (publ) 270 Thousand SEK 100.0%
Oncopeptides AB (publ) 35.22 Million SEK 100.0%
Pila Pharma AB (publ) 1.46 Million SEK 100.0%
Guard Therapeutics International AB (publ) - SEK NaN%
Scandinavian ChemoTech AB (publ) 2.82 Million SEK 100.0%
Simris Alg AB (publ) 4.35 Million SEK 100.0%
Diamyd Medical AB (publ) 130 Thousand SEK 100.0%
Xbrane Biopharma AB (publ) 238.72 Million SEK 100.0%
Ascelia Pharma AB (publ) - SEK NaN%
Diagonal Bio AB (publ) 23 Thousand SEK 100.0%